Our findings suggest that while patients with highly infiltrated, "hot" EOCs benefit from chemotherapy, women with "cold" EOCs may instead require DC-based vaccination to jumpstart clinically relevant anticancer immune responses.
over 2 years ago
Journal • Tumor Mutational Burden • IO biomarker
|
TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8)
DCVAC/OvCa and leukapheresis was not associated with significant safety concerns in this trial. DCVAC/OvCa sequential to CT was associated with a statistically significant improvement in PFS in patients undergoing first-line treatment of EOC.
P2, N=75, Not yet recruiting, Peking University Third Hospital | Trial completion date: Mar 2025 --> Apr 2027 | Trial primary completion date: Mar 2023 --> Oct 2024
over 3 years ago
Clinical • Trial completion date • Trial primary completion date